Rocky Mountain Laboratories, NIH/NIAID “Evaluation of new anti-prion drugs: from drug design to therapeutic efficacy against human prions in vitro, ex-vivo and in vivo”
|
Case Western Reserve University “The RAP approach for effective prevention and treatment of prion diseases”
|
Prion Research Center, Colorado State University “Use of Blood-borne Prion Amplification Assays for the Detection of Human Prion Diseases and Biomarker Assessment”
|
Department of Neurology, The University of Texas Health Science Center at Houston “Exploring the zoonotic potential of porcine-derived materials from animals exposed to infectious prions”
|
Istituto Superiore di Sanità, Dept. of Neuroscience, Rome “Investigating the influence of CYP4X1 gene on age at onset of CJD as potential preventive therapeutic approach”
|
Washington University School of Medicine “The Contribution of Rare Variant and Copy-Number Variation to Risk of Sporadic CJD and Pleiotropy with Other Neurodegenerative Diseases”
|
Broad Institute of MIT and Harvard “Assessing efficacy of zinc-finger repressors of prion protein as a therapeutic for prion disease”
|
The Mitchell Center for Alzheimer’s Disease and Related Brain Disorders; The University of Texas Health Science Center at Houston “Generating Recombinant Human Prions in Large Scale for Structural Studies”
|
University of Alberta, Edmonton, Alberta, Canada “Evaluating prion vaccines in transgenic mouse models of familial prion diseases”
|
Professor of Neurology, Harvard Medical School; and Translational Neurology Head of the Interdisciplinary Brain Center, Massachusetts General Hospital “Assessing long-term stability of cerebrospinal fluid PrP levels in genetic prion disease mutation carriers”
|
Laboratory of Prion Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy “Nanoparticle-mediated brain delivery of a tetracationic porphyrin with potent anti-prion activities”
|
National Institute of Allergy and Infectious Diseases, NIH “Cerebral neuronal dysfunction associated with human prion diseases”
|
Medical Research Council (MRC) Prion Unit at University College London “Development of a quantitative, real-time Protein-Misfolding by Cyclic Amplification (PMCA) reaction”
|
Professor, Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI “Determining the therapeutic potential of anti-PrP nanobody”
|
Center for Regenerative Medicine, Boston University School of Medicine “Modeling Creutzfeldt-Jakob Disease Using Human iPSC-derived Neurons”
|
Medical Research Council (MRC) Prion Unit at University College London “Investigating the relevance of blood DNA methylation signals for disease management in CJD”
|
Institute of Neuropathology, University Medical Center – Eppendorf, Hamburg, Germany “Investigating the Potential of the Neuroprotective N1 Fragment of the Prion Protein as a New Treatment Against Prion Diseases”
|
Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada “Isolation and Strain-Specific Characterization of Pathogenic CJD Prion Particles”
|
Department of Biochemistry, Boston University School of Medicine “Highly Synergistic Combination Therapy for Prion Diseases”
|
Rocky Mountain Laboratories, Montana “Investigation of Prion Inactivation by Reactive Oxygen Species in Vivo”
|
